• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心力衰竭合并糖尿病患者抗肾上腺素能治疗的批判性综述。

A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus.

作者信息

Tang W H Wilson

机构信息

Department of Cardiovascular Medicine, Cleveland Clinic, OH 44195, USA.

出版信息

Vasc Health Risk Manag. 2007;3(5):639-45.

PMID:18078015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2291308/
Abstract

Anti-adrenergic therapy has been widely accepted as an important therapeutic intervention in patients with chronic heart failure. However, there has been continuing controversy regarding the risks and clinical significance of metabolic effects of different anti-adrenergic drugs. This review summarizes what has been learned from clinical trial evidence regarding the benefits of anti-adrenergic drugs in diabetic patients with chronic heart failure.

摘要

抗肾上腺素能治疗已被广泛接受为慢性心力衰竭患者的一种重要治疗干预措施。然而，不同抗肾上腺素能药物代谢效应的风险和临床意义一直存在争议。本综述总结了从临床试验证据中所了解到的抗肾上腺素能药物对慢性心力衰竭糖尿病患者的益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7772/2291308/33f6b7a5c540/vhrm0305-639-02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7772/2291308/a9ed563dc1a2/vhrm0305-639-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7772/2291308/33f6b7a5c540/vhrm0305-639-02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7772/2291308/a9ed563dc1a2/vhrm0305-639-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7772/2291308/33f6b7a5c540/vhrm0305-639-02.jpg

相似文献

1
A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus.心力衰竭合并糖尿病患者抗肾上腺素能治疗的批判性综述。
Vasc Health Risk Manag. 2007;3(5):639-45.
2
Use of beta-blockers for heart failure in patients with diabetes mellitus.β受体阻滞剂在糖尿病患者心力衰竭治疗中的应用。
Postgrad Med. 2002 Nov;112(5 Suppl Unanswered):32-7. doi: 10.3810/pgm.11.2002.suppl22.118.
3
Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.糖尿病合并心力衰竭患者的管理方法：噻唑烷二酮类药物的作用
Am Heart J. 2004 Oct;148(4):551-8. doi: 10.1016/j.ahj.2004.04.033.
4
The impact of diabetes on heart failure: opportunities for intervention.糖尿病对心力衰竭的影响：干预机会
Curr Heart Fail Rep. 2007 Jun;4(2):70-7. doi: 10.1007/s11897-007-0003-8.
5
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.美托洛尔缓释片/控释片在糖尿病合并慢性心力衰竭患者中的疗效、安全性及耐受性：来自美托洛尔治疗慢性心力衰竭随机干预试验（MERIT-HF）的经验
Am Heart J. 2005 Jan;149(1):159-67. doi: 10.1016/j.ahj.2004.05.056.
6
Nonischemic heart failure in diabetes mellitus.糖尿病中的非缺血性心力衰竭。
Curr Opin Cardiol. 2008 May;23(3):241-8. doi: 10.1097/HCO.0b013e3282fcc2fa.
7
Ask the doctor. Is it okay to take a beta blocker if I have diabetes and heart failure?咨询医生。如果我患有糖尿病和心力衰竭，服用β受体阻滞剂是否安全？
Harv Heart Lett. 2003 Sep;14(1):8.
8
The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.糖尿病和微血管并发症对射血分数保留的心力衰竭患者预后的意义。
Diabetes Care. 2018 Jan;41(1):150-155. doi: 10.2337/dc17-0755. Epub 2017 Oct 19.
9
Advanced Glycation and ROS: a link between diabetes and heart failure.晚期糖基化与活性氧：糖尿病与心力衰竭之间的联系。
Curr Vasc Pharmacol. 2008 Jan;6(1):44-51. doi: 10.2174/157016108783331312.
10
Incretin therapy and heart failure.肠促胰岛素治疗与心力衰竭。
Circ J. 2014;78(4):819-24. doi: 10.1253/circj.cj-13-1561. Epub 2014 Mar 7.

本文引用的文献

1
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.在心力衰竭中，卡维地洛比美托洛尔更能有效预防血管事件：COMET研究结果。
J Am Coll Cardiol. 2007 Mar 6;49(9):963-71. doi: 10.1016/j.jacc.2006.10.059. Epub 2007 Feb 20.
2
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).美托洛尔和卡维地洛对慢性心力衰竭患者既往存在的糖尿病及新发糖尿病的影响：来自卡维地洛或美托洛尔欧洲试验（COMET）的数据。
Heart. 2007 Aug;93(8):968-73. doi: 10.1136/hrt.2006.092379. Epub 2007 Jan 19.
3
Diabetes in heart failure: prevalence and impact on outcome in the population.
心力衰竭中的糖尿病：人群中的患病率及其对预后的影响。
Am J Med. 2006 Jul;119(7):591-9. doi: 10.1016/j.amjmed.2006.05.024.
4
The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy.联合与选择性肾上腺素能阻滞对扩张型心肌病清醒犬左心室及全身血流动力学、心肌底物偏好和局部灌注的影响。
J Am Coll Cardiol. 2006 May 2;47(9):1871-81. doi: 10.1016/j.jacc.2005.11.082. Epub 2006 Apr 17.
5
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol.心肌梗死后，与美托洛尔相比，卡维地洛可改善胰岛素抵抗。
Clin Res Cardiol. 2006 Feb;95(2):99-104. doi: 10.1007/s00392-006-0336-4. Epub 2006 Feb 6.
6
Glycemic control and treatment patterns in patients with heart failure.心力衰竭患者的血糖控制与治疗模式
Heart Fail Monit. 2006;5(1):10-4.
7
The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.卡维地洛对糖尿病心力衰竭患者死亡风险的影响：一项荟萃分析的结果
Curr Med Res Opin. 2006 Feb;22(2):287-96. doi: 10.1185/030079906X80459.
8
Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?卡维地洛是否会损害无糖尿病的心力衰竭患者的胰岛素敏感性？
J Card Fail. 2005 Oct;11(8):590-4. doi: 10.1016/j.cardfail.2005.06.431.
9
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.HOPE研究中糖尿病和非糖尿病参与者的血糖异常与心血管及肾脏风险的关系：一项前瞻性流行病学分析
Diabetologia. 2005 Sep;48(9):1749-55. doi: 10.1007/s00125-005-1858-4. Epub 2005 Jul 30.
10
Association of poor glycemic control with prolonged hospital stay in patients with diabetes admitted with exacerbation of congestive heart failure.血糖控制不佳与因充血性心力衰竭加重而住院的糖尿病患者住院时间延长之间的关联。
Endocr Pract. 2004 Nov-Dec;10(6):467-71. doi: 10.4158/EP.10.6.467.